GlassScriptPhysician profile
William Burks
NPI 1356318190
$2,203.28
in general payments reported to CMS, 2019-2025
21 companies · $383 in 2025
The $383 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $19.56 · 2021: $428 · 2022: $370 · 2023: $491 · 2024: $295 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $525.40 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| New World Medical,INC. | $207.79 | 2023 | |
| Alcon Vision LLC | $162.19 | 2019-2024 | Hydrus Microstent, Clareon |
| Biotissue Holdings INC. | $138.63 | 2019-2022 | |
| Genentech USA, INC. | $138.05 | 2021 | |
| Mallinckrodt Hospital Products INC. | $132.91 | 2021-2023 | Acthar |
| Bausch & Lomb Americas INC. | $125.97 | 2024-2025 | Miebo, Xiidra, Scoutpro Osmolarity System |
| Allergan, INC. | $121.52 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $121.43 | 2019-2021 | |
| Horizon Therapeutics Plc | $94.89 | 2021-2022 | |
| Harrow Eye, LLC | $71.26 | 2025 | Vevye |
| Astellas Pharma US INC | $64.69 | 2025 | Izervay |
| Oyster Point Pharma, INC. | $58.95 | 2022-2024 | Tyrvaya, Ryzumvi |
| Johnson & Johnson Surgical Vision, INC. | $54.82 | 2019-2022 | |
| Glaukos Corporation | $46.60 | 2021-2025 | Idosetr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $41.11 | 2021 | |
| Sun Pharmaceutical Industries INC. | $24.78 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.06 | 2022 | |
| Eyevance Pharmaceuticals LLC | $19.07 | 2019 | |
| Shire North American Group INC | $15.20 | 2019 | |
| Thea Pharma INC. | $13.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Burks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.